BsaXI/RFLP analysis of initial or selectively reamplified PCR product is unreliable in detecting the V617F mutation in JAK2
Authors:
- 1 December 2010
- journal article
- research article
- Published by Wiley in International Journal of Laboratory Hematology
- Vol. 33 (3) , 267-271
Abstract
P>Introduction: Laboratory testing for the presence of the V617F mutation in JAK2 has taken on great importance in the diagnosis of myeloproliferative disorders. The availability of a facile detection method would bring this testing into greater clinical use. The polymerase chain reaction coupled with restriction fragment length polymorphisms is such a facile method. BsaXI cleaves the normal sequence but does not cleave the sequence leading to the V617F mutation. Methods: We have examined the use of selective PCR reamplification with BsaXI cleavage to enrich the fraction of V617F and compared the assignment of mutation with an established qPCR method. Results: We found that BsaXI fails to completely cleave normal sequence PCR product, leading to false positivity, particularly at low mutation levels. We also found that first-round standard PCR introduces new mutations in which subsequent reamplification and digestion cannot distinguish from the V617F mutation. Conclusion: This combination of problems effectively combines to render selective reamplification and redigestion unsuitable for detecting low fractions of the V617F mutation.Keywords
This publication has 17 references indexed in Scilit:
- Comparison of JAK2 V617F burden quantitation by two different quantitative‐polymerase chain reaction methodsInternational Journal of Laboratory Hematology, 2010
- Quantitative assay for the detection of the V617F variant in the Janus kinase 2 (JAK2) gene using the Luminex xMAP technologyBMC Medical Genetics, 2010
- The Type IIB restriction endonucleasesBiochemical Society Transactions, 2010
- JAK2 V617F Mutation Detection: Laboratory Comparison of Two Kits Using RFLP and qPCRGenetic Testing and Molecular Biomarkers, 2010
- Interlaboratory Development and Validation of a HRM Method Applied to the Detection of JAK2 Exon 12 Mutations in Polycythemia Vera PatientsPLOS ONE, 2010
- Clinical Performance of JAK2 V617F Mutation Detection Assays in a Molecular Diagnostics LaboratoryAmerican Journal of Clinical Pathology, 2009
- Myeloproliferative neoplasms: contemporary diagnosis using histology and geneticsNature Reviews Clinical Oncology, 2009
- Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disordersBlood, 2005
- A Gain-of-Function Mutation ofJAK2in Myeloproliferative DisordersNew England Journal of Medicine, 2005
- Methods and reagentsTrends in Biochemical Sciences, 1995